NFE2L2 and myeloid sarcoma: Based on the adaptive changes invoked, this coordinated modulation of signalling through Nrf2/Keap1 would be expected to produce a prolonged protective response in concomitant diseases where oxidative stress has been implicated relative to other disease-modifying MS treatments not acting on this pathway, including fingolimod, teriflunomide and glatiramer acetate [11].